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A non-nucleotide–bridged DNA decoy inhibits renal epithelial amounts without interfering with the physiologic func-
nitric oxide synthase expression. tion of NO generated by the constitutive isoforms of
Background. The expression of inducible nitric oxide syn- NOS. Previous studies have shown that the expressionthase (iNOS) is subject to strict tissue-specific transcriptional
of iNOS is subject to strict tissue-specific transcriptionalcontrol. In mouse renal epithelium, an interferon-g (IFN-g)-
control [1–3]. This characteristic of the enzyme raises theinduced signaling protein, IFN-g regulatory factor 1 (IRF-1),
appears to mediate the induction of iNOS expression by cyto- possibility of utilizing tissue differences in transcriptional
kines and bacterial lipopolysaccharide (LPS). control to design isoform- and possibly tissue-specific
Methods. We used a novel technique, namely, blockade of inhibitors of NO production.cytosolic IRF-1 activity with a triethyleneglycol-bridged decoy
We and others have previously demonstrated that theDNA oligonucleotide (ODN) containing the IRF-1 consensus
binding sequences present in the iNOS promoter to inhibit 59-flanking promoter region of the murine iNOS gene
iNOS gene expression. Cultured mouse renal epithelial cells contains many cis-acting regulatory elements that bind
were treated with a combination of LPS (1 mg/mL) and IFN to specific nuclear transcription factors and influence
(100 U/mL) in the absence or presence of IRF-1 decoy ODN
iNOS gene transcription [3, 4]. These elements includefollowed by determinations of NO production and iNOS pro-
binding sites for nuclear factor-kB (NF-kB) and inter-tein and mRNA expression.
Results. Treatment with IRF-1 decoy ODN resulted in con- feron-g regulatory factor 1 (IRF-1) [3 ,4]. IRF-1, an IFN-
centration-dependent inhibition of NO production and a marked responsive transcription factor involved in the induction
reduction in iNOS protein and mRNA levels. A scrambled of major histocompatibility complex (MHC) class I genesODN failed to affect LPS/IFN-stimulated NO production or
[5], has also been found to be an important mediatoriNOS protein and mRNA levels. Transcriptional assays showed
of the induction of iNOS expression by cytokines andthat the IRF-1 decoy ODN inhibited transcriptional activity
of an iNOS promoter-CAT gene construct. lipopolysaccharide (LPS) [6, 7]. IRF-1 expression is tran-
Conclusions. Decoy ODN-based techniques effectively in- scriptionally regulated by prior activation of immediate
hibit iNOS expression in renal epithelium and represent a poten-
transcription factors such as NF-kB and g-activated fac-tially useful approach for selective blockade of this enzyme in
tor (GAF) [8, 9]. Recently, it was shown that macro-pathologic conditions associated with excessive NO production.
phages from IRF-1∞ mice could not express iNOS activity
after stimulation with LPS [10].
In the kidney, NO has been implicated in the pathogen-
Selective inhibition of nitric oxide synthase (NOS) esis of tissue injury during ischemia/reperfusion [11–13],
activity has the potential for being an important thera- allograft rejection [14], and autoimmune glomerulone-
peutic tool to curtail excessive NO production in patho- phritis [15, 16]. Hence, selective inhibition of iNOS gene
logic states in which this molecule may be responsible for expression in the kidney during these conditions could
tissue injury. Selective inhibition of iNOS is of potentially potentially reverse or arrest tissue injury. Current meth-
greater significance because this will allow therapy to be ods available for achieving selective inhibition of gene
targeted at sites where NO is being produced in large expression include the use of oligonucleotides (ODNs).
The common ODN-based approaches of modulating ge-
netic expression involve the targeting of RNA with anti-Key words: interferon regulatory factor 1, transcription factor, triethyl-
ene glycol bridge, gene promoter. sense DNA or of DNA by the antigene or triplex approach
[12, 17–19]. A more novel approach is the targeting ofReceived for publication October 16, 1998
essential DNA-binding regulatory proteins or transcrip-and in revised form June 9, 1999
Accepted for publication August 20, 1999 tion factors with short sequences of double-stranded
ODNs containing the corresponding binding motifs pres- 2000 by the International Society of Nephrology
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ent in the promoter region of a gene (transcription factor 27-mer IRF-1 decoy ODN
59-ATATTTCACTTTCATAATGGAAAATTC-39decoy ODNs) [20–23]. Competitive binding of transcrip-
tion factors by these decoy ODNs prevent signaling pro- 39-TATAAAGTGAAAGTATTACCTTTTAAG-59
teins from entering the nucleus and binding to promoter
27-mer scrambled ODNDNA. One problem with this approach, however, has
59-TTACCATACGTCTTAAGTATATTAAAT-39been the rapidity with which unmodified ODNs are de-
39-AATGGTATGCAGAATTCATATAATTTA-59graded in serum and cell extracts by exonucleases [24–26].
Attempts to circumvent this problem involve the use of Cell cultures
phosphorothioated ODNs, which, although more stable,
Murine proximal convoluted tubule cells (MCTs) wereare also less lipid soluble.
grown as previously described [3]. The MCT cell linesIn this study, we used a novel approach to target DNA-
were kindly provided by Dr. Eric Neilson (University ofbinding regulatory proteins using double-stranded ODNs
Pennsylvania, Philadelphia, PA, USA) and by Drs. Juliewith non-nucleotide ethylene glycol linkers attached to
Ingelfinger and Shiow-Shih Tang (Massachusetts Gen-the ends of the duplex [27]. This ODN design reduces
eral Hospital and Harvard Medical School, Boston, MA,the rate of degradation, especially by exonucleases, and
USA). These cells were established from microdissectedincreases lipid solubility [27]. We report the use of triethyl-
mouse proximal tubules after stabilization by transfec-eneglycol-bridged IRF-1 decoy ODNs as an effective
tion with SV 40 virus and maintain many of the proper-isoform-specific approach to inhibit NO synthesis in re-
ties of differentiated proximal tubule epithelial cells [28].nal epithelium.
Nitrite assay
METHODS Nitrites were measured by spectrophotometry (543
nm) using the Griess reagent [0.75% sulfanilamide inChemicals and biologic products
0.5 N HCl and 0.075% N-(1-naphthyl)ethylenediamineCell culture media and materials were purchased from
dihydrochloride in double distilled water] as previouslyFisher Scientific (Orlando, FL, USA). Interferon-g (IFN;
described [29]. Nitrite concentrations were determinedrat recombinant) was purchased from GIBCO BRL (Gai-
by comparisons with a standard sodium nitrite curve withthersburg, MD, USA). cDNA probes were radiolabeled
double distilled water as blank and were expressed asusing a Stratagene (La Jolla, CA, USA) Prime-IT II ran-
nanomoles per milligram of protein. Preliminary studiesdom labeling kit. Other biologic products were from
showed that the presence of ODNs did not interfere withPromega Co. (Madison, WI, USA). LPS (E. coli serotype
the measurement of accumulated nitrites. Proteins were026:B6), sulfanilamide, sodium nitrite N-(1-naphthyl)ethyl-
determined by the method of Lowry [30].enediamine hydrochloride, and LDH assay kit were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
Northern analysis
Ethylene glycol-bridged decoy interferon-g regulatory Total RNA was isolated from MCT cells by acid-phe-
factor 1 oligonucleotides nol extraction, separated on agarose gel, and transferred
to Nytran nylon membrane (Schleicher and Schuell,The decoy IRF-1 ODNs were synthesized by DNAgency
Keene, NH, USA) as previously described [3, 31]. Mem-(Malvern, PA, USA), and the chemical ligation for the
branes were hybridized with a random, prime-labeled,final duplex formation was performed in our laboratory
([32P]dCTP) full-length murine macNOS-cDNA (cour-following previously described methods [27]. Briefly, the
tesy of Dr. Carl Nathan, Cornell University, New York,ODNs were dissolved in 0.05 mol/L sodium-4-morpho-
NY, USA) [32], a 125 base length IRF-1 DNA fragmentlinoethanesulfate buffer, pH 6.0, containing 20 mmol/L
(courtesy of Dr. Keiko Ozato, NIH, Bethesda, MD,MgCl2 and was treated with 1-[3-(dimethylamino)propyl]-
USA), or a monocyte chemoattractant protein-1 (MCP-1)3-ethylcarbodiimide hydrochloride (6.06 g/40 mL of solu-
cDNA probe (ATTC, Rockville, MD, USA) overnighttion) at 48C for three days with stirring. The ODNs were
at 458C followed by washing under low-stringency condi-then separated by ethanol precipitation. The IRF-1 de-
tions [2 3 SSPE, 0.2% sodium dodecyl sulfate (SDS),coy ODN consists of a 27 bp fragment corresponding to
508C] and a high-stringency wash (0.1 3 SSPE, 658C),the IRF-1 binding site identified between positions 2897
and exposed to an x-ray film. Membranes were strippedand 2913 in the promoter region of iNOS cloned from
and reprobed with [32P]dCTP-labeled b-actin DNA frag-mouse genomic DNA [3], as shown later in this article.
ment as gel loading control.A scrambled ODN containing the same base pairs but in
random order was also synthesized and used for control
Oligonucleotide probes and DNA gel mobility assaypurposes throughout the study. In addition, a second
Electrophoretic mobility shift assays (EMSAs) of nu-set of phosphorothioated IRF-1 decoy ODNs of similar
sequence were prepared for comparison purposes: clear extracts were performed as previously described
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in detail [3]. Briefly, the binding reaction was carried out control were added per 5 3 106 cells per 1 mL of pre-
warmed RPMI (378C, 10% Nuserum), containingby adding 10 mg nuclear extract to gelshift binding 5 3
buffer [10 mmol/L Tris-HCl, pH 7.5, 1 mmol/L MgCl2, DEAE-dextran (100 mg/mL) and 50 mmol/L Tris (pH
7.4). The pAiNOS-CAT construct consists of a 1749-0.5 mmol/L ethylenediaminetetraacetic acid (EDTA),
0.5 mmol/L dithiothreitol (DTT), 50 mmol/L NaCl, glyc- base upstream promoter region of iNOS cloned from
mouse genomic DNA by polymerase chain reaction anderol 4%, and poly(dI-dC)-poly(dI-dC) 50 mg/mL] con-
taining [g-32P]ATP-labeled double-stranded unbridged inserted into a promoterless pCAT-Basic vector (Pro-
mega Co.) upstream of the promoterless chlorampheni-decoy IRF-1 ODN probe in a total volume of 10 mL,
incubated at room temperature for 20 minutes, and the col acetyltransferase [3]. The suspension was then incu-
bated at 378C for 60 minutes followed by a three-minutereaction was terminated by the addition of 1 mL gel
loading 10 3 buffer (Tris-HCl 250 mmol/L, pH 7.5, bro- shock with 10% DMSO at room temperature. The cells
were washed and distributed to 100 mm plates each withmophenol blue 0.2%, xylene cyanol 0.2%, glycerol 40%).
The reactions were then run on a 4% nondenaturing about 5 3 106 cells in 10 mL of complete medium, and
incubated at 378C in 5% CO2. After 24 hours, the me-acrylamide gel prerun for 30 minutes before loading for
approximately three hours at 100 V. The gel was wrapped dium was changed and iNOS inducers added at the de-
sired concentrations and incubated for another 24 hours.in plastic and was exposed to x-ray film overnight.
The cells were then washed with ice-cold PBS, resus-
Western analysis pended in 0.25 mmol/L Tris-HCl (pH 8), and subjected
to three cycles of freezing and thawing. The lysates wereExpression of iNOS and IRF-1 proteins in whole cell
lysates was determined by Western analysis using a mono- centrifuged (11,700 g for 10 minutes at 48C), and the
supernatant was heated at 608C for 10 minutes to inacti-clonal antibody against macrophage iNOS and IRF-1
(Transduction Laboratories, Lexington, KY, USA), re- vate CAT inhibitors and was then centrifuged again as
spectively, as previously described [3]. Briefly, MCT cells described previously in this article. The supernatant was
were lyzed in 20 mmol/L Tris-HCl, pH 7.5, containing then assayed for CAT activity by thin layer chromatogra-
0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 2 phy (TLC). Data were expressed as the amount of chlor-
mmol/L EDTA, 0.5 mmol/L egtazic acid (EGTA), 10 amphenicol butyrylated per 100 mg of extract. Protein
mg/mL leupeptin, and 1 mg/mL aprotinin, centrifuged was determined as described by Bradford [33]. A
at 1000 r.p.m. for five minutes and homogenized on ice b-galactosidase reporter molecule was cotransfected into
with 30 strokes in an Eppendorf tube with a disposable the cells and b-galactosidase activity, measured using a
homogenizer. Cellular proteins were solubilized in so- commercial assay (Promega Co.) following manufactur-
dium dodecyl sulfate, separated by discontinuous poly- er’s instructions, was used to normalize the results of the
acrylamide gels (5% stacking, 7.5% resolving gel, 40 mA CAT assay.
for 5 hours), and transferred to a 0.45 mm nitrocellulose
Lactate dehydrogenase assaymembrane in 25 mmol/L Tris, pH 8.3, 150 mmol/L gly-
cine, and 20% vol/vol methanol for 15 hours at 100 mA. Aliquots of medium from cultured cells centrifuged
The nitrocellulose membrane was blocked with 10% at 250 g for four minutes were mixed with half of the
nonfat dry milk in phosphate-buffered saline (PBS) for amounts of lactate dehydrogenase (LDH) assay mixture
two hours and subsequently incubated with mouse anti– (Sigma Co.) and allowed to incubate at room tempera-
mac-NOS or anti–IRF-1 monoclonal antibodies (1/250) ture protected from light for 30 minutes. The reaction
for four hours at 208C. After washing the membrane to was then terminated by the addition of 1/10 volume of
remove excess antibody, peroxidase-labeled antimouse 1 N HCl, and the absorbance was measured at 490 nm.
secondary antibodies were applied, and the protein of The values were then expressed as a percentage of control.
interest was identified by enhanced chemiluminescence
Experimental design and statistical analysis(ECLe; Amersham Corp., Arlington Heights, IL, USA).
Where indicated, statistical analysis was performed
Chloramphenicol acetyltransferase (CAT) assays using Student’s t-test for paired and unpaired data. The
Murine proximal convoluted tubule cells were trans- results are presented as mean 6 se of the indicated
fected by a modification of the DEAE-dextran method, number of experiments. Each blot shown is a representa-
as described elsewhere [3]. Briefly, the cells were seeded tive example of a series of experiments performed on at
the day before transfection such that they were approxi- least three separate occasions.
mately 60% confluent the next day. After cells were
washed twice with PBS, trypsinized, and resuspended in
RESULTSRPMI with 10% Nuserum (Becton Dickinson, Bedford,
To confirm the specificity of binding of the triethyl-MA, USA), 10 mg of plasmid DNA (pAiNOS-CAT con-
struct) and 8 mg of decoy IRF-1 ODN or scrambled eneglycol-bridged decoy ODN to IRF-1, we performed
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Fig. 1. Electrophoretic mobility gel shift assay showing competitive Fig. 2. Electrophoretic mobility gel supershift assay using an anti–IRF-1
displacement of radiolabeled interferon-g regulatory factor-1 (IRF-1) monoclonal antibody (1/250) in nuclear extracts of murine convoluted
oligonucleotide (ODN) probe from nuclear IRF-1 protein binding by tubule (MCT) cells treated with IFN (100 U/mL for 2 hours). An
triethyleneglycol-bridged IRF-1 decoy ODN. Probe lane represents addition of the antibody causes a shifted band (second lane from the
electrophoresis of radiolabeled IRF-1 ODN in the absence of nuclear left) that is competitively displaced by the IRF-1 decoy ODN (dc) but
extract. The control lane represents binding reaction of radiolabeled not by the scrambled ODN (sc).
IRF-1 ODN probe to IRF-1 in nuclear extracts from untreated cells.
Treatment with IFN increases nuclear IRF-1. Incubation of nuclear
extracts from IFN-treated cells with bridged IRF-1 decoy ODN (dc)
displaces the IRF-1 ODN probe from its binding to IRF-1, whereas
bridged scrambled ODN (sc) has no effect. marked increase in accumulated nitrites in the culture
medium, which was inhibited in a concentration-depen-
dent manner by IRF-1 decoy ODN added to the culture
medium simultaneously with the iNOS inducers (maxi-EMSA and supershift assays of nuclear extracts from
mal inhibition of 93% with 0.8 mg/mL of ODN; Fig. 3A).MCT cells treated with IFN (100 U/mL for 2 hours)
For comparison purposes, under similar experimentalusing an identical but unbridged radiolabeled double-
conditions, the phosphorothioated IRF-1 decoy ODNstranded IRF-1 consensus ODN as probe and 100-fold
inhibited nitrite production only when transfected intoexcess unlabeled bridged IRF-1 decoy ODN in a compe-
cells (DEAE dextran method, discussed earlier in thistition assay. Unbridged ODN was used as probe because
article) and resulted in maximal inhibition of only 69%bridged decoys lack free ends and are difficult to radiola-
using a concentration of 4.8 mg/mL (data not shown).bel. Treatment with IFN increased nuclear IRF-1 binding
Contrary to the effect of the bridged IRF-1 decoy ODN,as compared with untreated controls (Fig. 1, lanes 1
treatment with the scrambled bridged ODN failed toand 2). Excess unlabeled bridged IRF-1 decoy ODN
inhibit nitrite production significantly at concentrationsdisplaced the radiolabeled ODN from IRF-1 binding,
up to 0.8 mg/mL (Fig. 3B). At higher concentrations,whereas excess unlabeled scrambled ODN had no effect
scrambled bridged ODN also caused some inhibition of(Fig. 1, lanes 3 and 4). To confirm this finding, we used
nitrite production. This inhibition was smaller than thatan anti–IRF-1 monoclonal antibody in a supershift assay
caused by IRF-1 decoy ODN and is likely due to nonspe-of nuclear extracts from cells treated with IFN using the
cific effects of ODNs, as has also been described by otherprobe described earlier. As illustrated in Figure 2, the
investigators [34, 35]. In subsequent experiments, IRF-1anti–IRF-1 monoclonal antibody produced a shifted band
decoy and scrambled ODNs were used at a concentration(lane 2) that was not affected by adding 100-fold excess
of 0.5 mg/mL in order to minimize this nonspecific effect.scrambled ODN but could be competed out with a simi-
To confirm that the inhibitory effect of the IRF-1 de-lar concentration of bridged IRF-1 decoy ODN (lanes
coy ODN on nitrite production was not due to cell toxic-3 and 4, respectively). Thus, these competition studies
ity, we measured LDH activity in the culture media ofconfirm the specificity of binding of the bridged IRF-1
control MCT cells and MCT cells treated with LPS anddecoy ODN to nuclear IRF-1.
IFN in the presence or absence of varying concentrationsNext, we examined the effect of the bridged IRF-1
of IRF-1 decoy and scrambled ODNs (up to ODN con-decoy ODN on iNOS activity. In preliminary experi-
centrations of 1 mg/mL). LDH activity was not differentments, the bridged IRF-1 decoy ODN exerted similar
between the groups (data not shown).inhibitory effects on iNOS activity regardless of whether
To determine the effect of IRF-1 decoy ODN onit was transfected into MCT cells by chemical methods
steady-state iNOS mRNA and iNOS protein, we co-or added in solution into the culture medium simultane-
treated cells with LPS/IFN (1 mg/mL:100 U/mL) for 6ously with the iNOS inducers. Therefore, all experiments
and 12 hours, respectively, in the presence or absencepresented here were performed using the latter method.
of IRF-1 decoy or scrambled ODN. As shown in Figure 4,Treatment of MCT cells with a combination of LPS (1
mg/mL) and IFN (100 U/mL) for 24 hours resulted in a IRF-1 decoy ODN markedly reduced LPS- and IFN-stim-
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ODNs inhibit iNOS expression at the transcriptional
level, we examined their effect on MCT cells transiently
transfected with a pAiNOS-CAT construct. Transfected
MCT cells were treated with a combination of LPS (1
mg/mL) and IFN (100 U/mL) in the presence or absence
of IRF-1 decoy or scrambled ODN, and CAT assays
were performed after 24 hours. Treatment with LPS/
IFN resulted in a significant increase in CAT activity
that was completely inhibited by cotreatment with IRF-1
decoy ODN but not by scrambled ODN (Fig. 5). These
experiments demonstrate that the IRF-1 decoy ODN in
fact acts by inhibiting transcriptional activity of the iNOS
gene promoter and iNOS gene transcription.
We also investigated the effect of the IRF-1 decoy
ODN on steady-state IRF-1 mRNA following treatment
with LPS (1 mg/mL) and IFN (100 U/mL) for two hours.
As shown in Figure 6, neither the IRF-1 decoy ODN
nor the scrambled ODN had any significant effect on
steady-state IRF-1 mRNA levels. This observation is
also consistent with a gene-selective effect of the IRF-1
decoy ODN because expression of the IRF-1 gene is not
dependent on transactivation by IRF-1 protein. Immu-
noreactive IRF-1 protein levels measured six hours fol-
lowing LPS and IFN treatment were somewhat reduced
by the IRF-1 decoy ODN (Fig. 6). However, there was
no difference between control and IRF-1 decoy ODN-
treated cells when IRF-1 protein levels were measured
10 hours following LPS and IFN treatment. This period
(10 hours) corresponds to the time of peak IRF-1 protein
expression after LPS and IFN stimulation in MCT cells.
These studies suggest that the mechanisms of the inhibi-
Fig. 3. Effect of increasing concentrations of bridged IRF-1 decoy tory effect of the IRF-1 decoy ODN on iNOS gene tran-
ODN (A) and scrambled ODN (B) on nitrite production by MCT cells scription do not involve inhibition of IRF-1 mRNA ex-(*P , 0.05 vs. L/I, N 5 12; L/I, LPS plus IFN treatment).
pression and support the notion that the IRF-1 decoy
ODN acts by interfering with nuclear binding of IRF-1
protein.
ulated iNOS mRNA expression, whereas the scrambled To confirm the gene selectivity of the IRF-1 decoy
ODN had no significant effect (densitometry values 5 ODNs, we investigated their effect on the LPS-induced
1268 6 14, 259 6 55, and 1233 6 120 arbitrary units for expression of MCP-1, an NF-kB–dependent gene. As
LPS/IFN, LPS/IFN 1 IRF-1 decoy ODN, and LPS/IFN 1 illustrated in Figure 7, MCP-1 mRNA expression was
IRF-1 scrambled ODN, respectively; N 5 3, P # 0.05 for markedly induced by LPS, and this induction was not
LPS/IFN vs. LPS/IFN 1 IRF-1 decoy ODN). Similarly, affected by treatment with the IRF-1 decoy ODN.
IRF-1 decoy ODN caused a significant reduction in LPS-
and IFN-stimulated iNOS protein expression, whereas
DISCUSSIONthe scrambled ODN had no significant effect (densitome-
The functional diversity and marked differences intry values 5 1747 6 27, 857 6 15, and 1568 6 89 arbitrary
the regulation of expression of NOS isoforms pose aunits for LPS/IFN, LPS/IFN 1 IRF-1 decoy ODN, and
challenging problem for therapeutic targeting of this en-LPS/IFN 1 IRF-1 scrambled ODN, respectively; N 5
zyme in situations in which excessive production of NO3, P # 0.05 for LPS/IFN vs. LPS/IFN 1 IRF-1 decoy
leads to cell injury. In the kidney, for example, inhibitionODN). These studies demonstrate that the IRF-1 decoy
of NOS by nonselective l-arginine based compounds toODN inhibits iNOS activity by decreasing iNOS mRNA
ameliorate inflammatory injury is also likely to perturband protein expression and is thus consistent with tran-
the activity of the constitutive isoforms of NOS that arescriptional inhibition of iNOS gene expression by the
responsible for the maintenance of renal perfusion anddecoy ODN.
To investigate further whether or not IRF-1 decoy macula densa function.
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Fig. 4. Effects of bridged IRF-1 decoy (dc) and scrambled (sc) ODNs on (A) iNOS protein and (B) steady-state iNOS mRNA levels in MCT
cells treated with a combination of LPS (1 mg/mL) and IFN (100 U/mL) for 12 and 6 hours, respectively.
tent with results of previous studies indicating that this
region contains two adjacent sites for IRF-1 binding and
homodimerization, both of which are required for full
IFN action on iNOS gene expression [6, 7]. These and
other studies illustrate the considerable complexity and
tissue specificity of the mechanism that regulates the
expression of iNOS activity in various cells [36–38].
Therefore, if the signaling mechanisms for activation of
iNOS in a specific cell or tissue are well delineated, one
could theoretically design decoy ODNs that selectively
block undesirable NOS activity without generalized inhi-
bition of NOS activity in tissues where NO production
may be physiologically necessary.
To overcome the lack of selectivity and specificity of
classic NOS inhibitors, we used a decoy ODN strategy
to target IRF-1 in an attempt to inhibit iNOS activity in
mouse renal proximal tubule epithelium. The decoy
Fig. 5. Effect of bridged IRF-1 decoy (dc) and scrambled (sc) ODNs ODN was designed to include both IRF-1 binding sites
on transcriptional activity of the iNOS promoter in MCT cells following mentioned earlier in this article. The most important
induction with LPS and IFN (N 5 4; L/I, LPS plus IFN treatment).
findings of this study are that a DNA decoy ODN tar-
geted to bind IRF-1 competitively (a) inhibits the induc-
tion of iNOS activity by LPS and IFN, (b) reduces steady-
state iNOS mRNA levels and iNOS protein synthesis,In a previous report, we demonstrated differences be-
(c) inhibits iNOS gene transcription, and (d) decreasestween renal tubular epithelium and macrophages in the
the levels of immunoreactive IRF-1 protein without sig-pattern of NF-kB dimers activated and translocated to
nificantly affecting IRF-1 mRNA expression. These ef-the nucleus in response to cytokines [3]. Preliminary
fects are likely the result of binding of endogenous IRF-1evidence from our laboratory also suggests that mouse
by decoy DNA, which would block the ability of thisrenal epithelial iNOS requires the prior activation of an
protein to bind to its recognition site in the iNOS geneinducible protein for its expression. This protein is likely
promoter. We do not have an explanation, however,IRF-1, a DNA-binding regulatory protein that is induced
for the somewhat surprising decrease in immunoreactiveby IFN treatment [6, 7]. Deletion of the IRF-1 DNA
IRF-1 protein observed after six hours of LPS and IFNbinding site corresponding to the sequence between posi-
treatment in decoy DNA-treated cells. One can specu-tions 2897 and 2913 of the mouse renal tubular epithe-
late that exclusion of IRF-1 from nuclear binding maylial iNOS gene promoter results in loss of the synergistic
result in a decrease in its half-life, although the absenceeffect of IFN on iNOS gene expression (abstract; Guz-
man et al, J Am Soc Nephrol 7:1701, 1996). This is consis- of differences in the IRF-1 protein levels measured after
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Fig. 6. Effect of bridged IRF-1 decoy (dc) and scrambled (sc) ODNs on (A) IRF-1 protein and (B) steady-state IRF-1 mRNA levels in MCT
cells treated with a combination of LPS (1 mg/mL) and IFN (100 U/mL). IRF-1 protein was measured after 6 and 10 hours of LPS and IFN
treatment, and iNOS mRNA was measured after 2 hours of similar treatment.
hibit iNOS activity in pathologic conditions [12, 39].
However, antisense ODNs are designed to bind con-
served regions of the iNOS gene and thus are unable to
target tissues in a specific manner. Investigation of the
different nuclear signaling proteins that confer tissue-
specificity to the iNOS gene response is undoubtedly an
important task because identification of these proteins
should allow us to design decoy ODNs tailored to be
more selective and specific. Other reports have also dem-
onstrated the use of phosphorothioated decoy ODNs in
inhibiting gene expression, including the inhibition of
smooth muscle proliferation after vascular injury [20],
as well as the inhibition of mesangial cell proliferation
[23], iNOS activity [34], HIV virus replication [40], Tat
protein-induced transcriptional activation in HIV [41],
and tumor cell growth [42]. This study takes advantage of
a novel non-nucleotide (triethyleneglycol)-bridged decoyFig. 7. Effect of bridged IRF-1 decoy (dc) ODN on LPS stimulation
(1 mg/mL for 2 hours) of MCP-1 mRNA expression. ODN design that increases lipid solubility and resistance
to exonuclease digestion [24–26]. Therefore, smaller con-
centrations of ODN can be used, thereby limiting non-
specific and toxic effects. Interestingly, in preliminary ex-10 hours of LPS and IFN treatment between control and
periments, bridged decoy ODNs were several-fold moredecoy DNA-treated cells makes this possibility unlikely.
potent than phosphorothioated decoy ODNs in inhib-It is also possible that binding of members of the IFN-
iting iNOS and were taken up very avidly by cells, thusresponsive group of transcription factors that have avid-
obviating the need for a transfection procedure. Anotherity for the same DNA sequence than IRF-1 (for example,
unique aspect of this study is the choice of IRF-1 as aIRF-2) may occur and be responsible for other unex-
target because this protein is less ubiquitous and appearspected effects. Our studies, however, were not designed
to serve more discrete and specialized functions thanto address these specific questions.
other previously targeted factors such as NFkB, a tran-Our current study demonstrates that bridged decoy
scription factor involved in the activation of a large num-ODNs can be effectively used to block selectively gene
ber of genes [34, 41, 42]. The gene selectivity of thetranscription in vitro. This approach represents a poten-
IRF-1 decoy ODN approach used in this study is demon-tially important new avenue for the development of ther-
strated by the lack of effect of these ODNs on the expres-apeutic alternatives aimed at selectively inhibiting iNOS
sion of genes that are primarily driven by NFkB and areactivity in situations in which excessive production of
not IRF-1 dependent such as IRF-1 itself and MCP-1NO is deleterious.
Other investigators have used antisense ODNs to in- [43–45].
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transcription of a major histocompatibility class I gene via a 59In the kidney, NO plays important physiological roles
interferon consensus sequence. Mol Cell Biol 7:2625–2630, 1987
such as tubuloglomerular feedback and maintenance of 6. Martin E, Nathan C, Xie Q: Role of interferon regulatory factor
renal blood flow [46]. However, excessive renal produc- 1 in induction of nitric oxide synthase. J Exp Med 180:977–984,
1994tion of NO in conditions such as autoimmune glomerulo-
7. Spink J, Evans T: Binding of the transcription factor interferonnephritis, renal ischemia/reperfusion, and allograft rejec- regulatory factor-1 to the inducible nitric oxide synthase promoter.
tion has been reportedly associated with worsening of J Biol Chem 272:24417–24425, 1997
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